
# **ACL Laboratories COVID-19 and Influenza Activity Report**

Updated: Oct 10, 2021




					RES	SPIR/	TOR	Y PA	THO	GEN	I PAI	NEL (	Oct 10	), 202	21 Pos	sitivity	/ Rate	(%)					
MONTH	FLU A Total	FLU A (H1N1)	2009 (H1N1)	FLU A (H3N2)	FLU B	RSV A	RSV B	RSV Total	PARA 1	PARA 2	PARA 3	PARA 4	Corona 229E	Corona NL63	Corona OC43	Corona HKU1	Meta pneumo	Entero Rhino	ADENO	BOCA	Legio nella	Chla mydia	Myco plasma
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	0.2	0.0	0.1
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1
JUL	0.0	0.0	0.0	0.0	0.0	1.0	7.2	8.2	0.1	0.5	12.9	0.0	0.1	0.4	1.4	0.0	0.5	18.9	1.6	4.4	0.4	0.0	0.0
AUG	0.0	0.0	0.0	0.0	0.0	0.8	12.5	13.3	0.0	1.2	6.2	0.1	0.1	0.1	0.5	0.0	0.7	14.0	1.3	3.6	0.0	0.0	0.0
SEP	0.0	0.0	0.0	0.0	0.0	0.7	10.6	11.3	0.0	0.9	1.8	0.4	0.0	0.0	0.4	0.0	0.6	23.6	0.8	4.1	0.1	0.0	0.1
ОСТ	0.0	0.0	0.0	0.0	0.0	1.0	6.2	7.1	0.0	1.2	1.2	0.5	0.2	0.0	0.0	0.0	0.2	24.3	1.0	6.2	0.0	0.0	0.0
NOV																							
DEC					_						_	_											


Increased prevalence of viruses: Rhinovirus, RSV and Boca virus



ACL RSV PCR remains the same, EIA pos rate is trending down


## CDC Data RSV pos rate for Region 5 Chicago - (PCR – 21% $\downarrow$ ), Antigen - 32% $\downarrow$ )







Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG	IL % RSVAG	WI % RSVAG	IL % RSVPCR	WI % RSVPCR
Oct 10	4.3	7.6	5.0	18.2	0	0.2	0	0 (	22.2	31.8	23.9	32.6
Oct 3	5.0	8.6	6.0	16.6	0	0	0	0	20.0	34.0	24.9	35.5
Sep 26	5.0	8.1	4.4	15.2	0	0	0	0	27.7	35.9	30.0	37.7
Sep 18	4.9	9.0	7.2	17.5	0	0	0	0	33.0	31.0	28.0	39.6
Sep 12	6.5	9.6	5.9	20.5	0	0	0	0	20.0	21.9	41.6	43.7
Sep 5	6.2	8.3	7.0	22.4	0	0	0	0	33.3	43.9	38.1	40.5
Aug 29	7.5	8.5	9.0	21.3	0	0	0	0	38.9	32.5	43.9	38.8
Aug 22	6.0	7.3	13.5	16.1	0	0	0	0	31.3	27.1	32.5	20.6
Aug 15	6.6	6.8	9.8	18.0	0	0	0	0	22.9	23.5	27.0	16.7
Aug 8	6.8	7.4	9.8	15.8	0	0	0	0	16.6	22.7	25.7	16.9
Aug 1	3.8	6.9	10.5	17.6	0	0	0	0	14.9	20.0	0.0	0.0
Jul 25	2.7	4.1	8.0	11.8	0	0	0	0	15.5	16.7	0.0	0.0

ACL RSV tests results are consistent with "atypical" RSV outbreak






Oct 6, 2021 - daily COVID-19 cases in US - CDC





### Oct 2, 2021 – SARS-CoV-2 circulating in the US (~99.5% % Delta variants)



### US vaccination status CDC | Data as of: Oct 5, 2021

399,552,444 Vaccines Administered 216,268,034 186,618,184 People who received at People who are fully least one dose vaccinated\* 65.1% 56.2% Percentage of the US Percentage of the US population that has population that has received at least one been fully vaccinated\* dose






According to the WHO's August 2021 influenza update, global flu activity (including southern hemisphere) has remained at <u>lower than expected levels</u> for this time of year, which they believe may be due to continued COVID-19 measures like physical distancing and masking. (Most targets in circulation were - Flu B and Flu A H3)

What's New for 2021-2022 - A few things are different for the 2021-2022 influenza (flu) season, including:


The composition of flu vaccines has been updated.

- 1. All flu vaccines will be **quadrivalent (four components)** for four different flu viruses.
- 2. Flucelvax Quadrivalent is now approved for people **2 years and older**.
- 3. **Flu and COVID-19** vaccines can be given at the same time.
- 4. Guidance concerning contraindications and precautions for the use of two flu vaccines **Flucevax and Flublok Quadrivalent** were updated.

# CSF targets positivity rate is 5.7%



# The most prevalent GI bacterial target are (Giardia -0.5%)



# The most prevalent GI viral target is - (Norovirus II - 0.2%)

